Stay updated on iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial

Sign up to get notified when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Updates appear limited to metadata and formatting on the study page, with no changes to core study details (design, eligibility criteria, primary/secondary outcomes, enrollment, or listed locations). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-10-27T21:10:14.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Major update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.
    Difference
    3%
    Check dated 2025-10-06T08:54:44.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Update page revision to v3.1.0 and replace/expand topics from Colorectal Cancer and Rectal Diseases to Colonic Neoplasms.
    Difference
    0.4%
    Check dated 2025-09-29T07:34:02.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.
    Difference
    0.2%
    Check dated 2025-09-14T23:19:51.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.2%
    Check dated 2025-09-07T19:54:05.000Z thumbnail image
  8. Check
    62 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as new medical topics related to colorectal cancer and various therapeutic agents. Notably, several specific names of researchers and studies have been included, enhancing the page's relevance in the medical field.
    Difference
    8%
    Check dated 2025-08-31T12:32:39.000Z thumbnail image

Stay in the know with updates to iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.